Tag: covid-19 fayetteville

Carolina Institute for Clinical Research Begins Recruiting Healthy Adults for COVID-19 Vaccine Clinical Trial

Fayetteville, NC; August 10, 2020 – Carolina Institute for Clinical Research announced today it has begun recruiting healthy adults for a Phase 3 clinical research study to evaluate the safety and effectiveness of mRNA-1273, a vaccine candidate against COVID-19. Sponsored by Moderna, the COVE Study is recruiting healthy volunteers ages 18 or older in high-risk populations, including the elderly, racial and ethnic minorities at higher risk for COVID-19, and essential workers in close contact with potentially infected persons.

The Phase 3 study will evaluate if mRNA-1273 boosts the immune system to produce enough antibodies against SARS-CoV-2, the virus that causes COVID-19, so it does not cause illness in case of infection.

“We are excited and hopeful as we begin participating in the COVE Study, understanding this is one of the most important and impactful clinical research studies in our lifetime,” said Dr. Grach, CEO, Wake Research. “We encourage individuals across the Fayetteville area to consider participating in this trial, which could bring the world one step closer to ending this global health crisis.”

To be eligible for the study, healthy volunteers must be 18 years of age and older with no known history of SARS-CoV-2 infection or previous participation in an investigational coronavirus vaccine. Within this population, Carolina Institute for Clinical Research is prioritizing candidates whose locations or circumstances put them at higher risk of exposure to the virus, including:

  • Elderly, ages 65 and older
  • Essential workers in close contact with potentially infected persons, including, but not limited to, healthcare and hospital workers, first responders, transit employees, institutional residents or workers, factory employees, and teachers and students
  • Racial and ethnic minorities at high risk for COVID-19

If a person is eligible and decides to participate, the research staff at Carolina Institute for Clinical Research will randomize patients to receive either the mRNA-1273 vaccine or a matching placebo. The total length of participation is 25 months and includes approximately seven visits to the clinic and 24 phone calls.

Carolina Institute for Clinical Research is one of 89 research sites across the country participating in the COVE Study. If someone is interested in participating in clinical research in their area, call

(910) 302-8151 or visit www.ci-cr.com/ to learn more.

About Carolina Institute for Clinical Research

Carolina Institute for Clinical Research is a multi-disciplinary clinical research site that brings many years of experience and leadership in the research community to the Fayetteville area. Our research site effectively combines strategic accelerated volunteer recruitment and retention with high-quality clinical trial conduct practices. Our approach is uncompromising – each study conducted at our site is carefully planned and executed according to protocol and regulations with superior quality.

Media Contact

Andrea Clement
[email protected]

CICR Now Enrolling For COVID-19 Clinical Trials, Testing, Vaccine, and Treatment

Wake research provides investigational health services to COVID patients nationwide via the newest clinical research trials

Seven Sites Now Enrolling for COVID-19 Vaccine Trials, Testing, Inpatient and Outpatient COVID Treatment Studies

(Raleigh, NC) June 22, 2020– Wake Research, a national leader in clinical research and one of the largest Phase I-IV clinical trial service companies in North America, announces the commencement of several new clinical research trials to help patient communities battle the COVID-19 pandemic, including trials for COVID vaccines, COVID diagnostic testing, and inpatient and outpatient care for patients with COVID-19. Seven Wake Research sites in six states will be participating in the trials, including North Carolina, Georgia, Tennessee, California, Nevada, and Texas.

“We are excited to be able to participate in these trials and to offer ground-breaking investigational treatment to COVID patients (inpatient and outpatient) across the country,” states Ella Grach, MD, President and Chief Executive Officer of Wake Research. “Our entire team is working diligently to assure patient safety in compliance with CDC and local public health authorities’ guidelines while maintaining the highest quality and integrity metrics, and streamlining processes to ensure the most efficient and effective patient care and recruitment rates. Our best defense against the global pandemic is efficient and well-run clinical trials providing high integrity data toward the discovery of new treatments,”  she adds.

COVID Clinical Trial Locations and Patient Information

Several of the Wake Research COVID-19 clinical studies are being conducted in partnership with local hospitals, particularly for inpatient treatment of COVID patients:

Fayetteville, NC – A COVID-19 inpatient treatment trial initiated the first week of June, at the CICR site in Fayetteville, in partnership with Cape Fear Valley Hospital nearby. 1841 Quiet Cove, Suite 2, Fayetteville, NC 28304. For more information, call (910) 302-8151 or visit www.ci-cr.com. Inpatient and outpatient treatments.

Las Vegas, NV – Through Wake Research’s site in the Las Vegas area, CRCN, there will be both out-patient and inpatient COVID trials conducted in partnership with a local hospital: 1012 E Sahara Ave, Las Vegas, NV 89104. For more information, call (702) 893-8968 or visit www.crcnevada.com. Inpatient and outpatient treatments, vaccine, and COVID test.

Other locations for Wake Research COVID-19 clinical trials include:

  • Raleigh, NC – Outpatient treatment, vaccine, and COVID-19 test. Wake Research site – 3100 Duraleigh Rd., Suite 304, Raleigh, NC 27612. For more information, call (919) 781-2514 or visit www.wakeclinical.com.
  • Atlanta, GA – Outpatient treatment. Mount Vernon location of Wake Research. 755 Mount Vernon Highway NE, Suite 200, Atlanta, GA 30328. For more information, call (404) 419-1857 or visit mvclinical.com.
  • Chattanooga, TN – Outpatient treatment. 6035 Shallowford Rd., Suite 109, Chattanooga, TN 37421. For more information, call (423) 698-4584 or visit


  • San Diego, CA – COVID-19 test and outpatient treatment. 9040 Friars Rd., Suite 540, San Diego, CA 92108. For more information, call (619) 521-2841 or visit www.mccresearch.com.
  • Dallas, TX – COVID-19 test and outpatient treatment. Global Medical Research. 2701 S. Hampton Rd. Suite 250, Dallas TX, 75224. For more information, call (972) 996-5645 or visit globalmedicalresearch.us.

Potential patients interested in learning more and potentially enrolling in a study may visit www.wakeclinical.com. If selected to participate in a study, patients are compensated for their time and travel.

“In addition to receiving the highest quality of care from some of the best physicians in the clinical research field, participants in these studies are contributing to the future of medicine, providing key insights and data needed to develop a treatment or vaccine for COVID-19,” Dr. Grach states. “The first wave of Covid-19 Infection in many places is getting under control. That is a great accomplishment, and it’s really crucial that we use this window of opportunity to conduct clinical trials to develop much needed treatments,” she concludes.

Wake Research is owned by M3, Inc., a global healthcare services company with businesses in more than a dozen countries, including medical research, media, and workforce/staffing services. For more information, visit https://www.wakeresearch.com.

About Wake Research, Inc.:

M3-Wake Research is an organization of integrated investigational sites, committed to excellence, working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device and pharmaceutical industries. M3-Wake Research’s 16 sites are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications.

M3-Wake Research is known for effectively combining strategic volunteer recruitment, rapid trial start-up, and subject enrollment/retention with high-quality clinical trial conduct, using standardized operating procedures and centralized marketing and advertising to ensure rapid subject enrollment. M3-Wake Research sites have conducted more than 7,000 research studies for hundreds of pharmaceutical and biotech sponsors and CROs. Wake Research’s mission is to bring novel medications, biologics, and devices through clinical research to as many people as possible while providing unparalleled service and exceptional value to clinical trial partners and stakeholders.

About M3 Inc.:

M3 Inc. operates in the US, Asia, and Europe with over 4 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net, and medlive.cn. M3 Inc. is a publicly-traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including the USA, UK, Japan, S. Korea, and China. M3 Inc. provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, Beijing, and Seoul.

Our Staff Discusses COVID-19 Crisis on WPTF Podcast

Aubrey Farray is the Phase I clinical manager for Wake Research, the headquarters of the site network CICR belongs to. He recently spoke with hosts Jason Kong (WPTF) and Nicole Clagett (Transitions GuidingLights) of WPTF’s Aging Well podcast on clinical trials in the COVID-19 crisis.  In the interview, he details the process of clinical trials, explaining what participating in a clinical trial entails for those who have questions, and discusses how the elderly population can still participate in ongoing clinical trials, and do so safely.

Farray also tells Aging Well how Wake Research is keeping current clinical trials safe for all participants during the COVID-19 crisis and emphasizes the important role clinical trials have right now in researching and testing drugs to treat COVID-19.

Listen to the full interview here:

Aging Matters Podcast:http://curtismediagroup.hipcast.com/rss/eyeonehealth.xml